AYTU BIOPHARMA, INC — Director's Dealing 2016

Jul 11, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AYTU BIOSCIENCE, INC (AYTU)
CIK: 0001385818
Period of Report: 2016-07-07

Reporting Person: MACALUSO MICHAEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-07	Common Stock	A	65000	$0.00	Acquired	94780	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-07	Stock Option Grant	$18.12	D	10417	Disposed	2025-11-11	Common Stock (10417)	Direct
2016-07-07	Stock Option Grant	$3.23	A	10417	Acquired	2025-11-11	Common Stock (10417)	Direct
2016-07-07	Stock Option Grant	$6.72	D	8334	Disposed	2026-04-10	Common Stock (8334)	Direct
2016-07-07	Stock Option Grant	$3.23	A	8334	Acquired	2026-04-10	Common Stock (8334)	Direct
2016-07-07	Stock Option Grant	$3.23	A	22500	Acquired	2026-07-07	Common Stock (22500)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option Grant	$18.12	2025-11-11	Common Stock (10417)	10417	Direct
Stock Option Grant	$6.72	2026-04-10	Common Stock (8334)	8334	Direct

Footnotes

F1: These are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.

F2: The number of shares has been decreased and the exercise price has been increased to reflect the twelve-for-one stock split effected on June 30, 2016.

F3: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. These options are 100% vested.

F4: 25% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as an employee on such dates.